Our results are hypothesis generating and inform the design of clinical trials where patients are stratified using CD8+ T cell count as a biomarker to receive either RT+CON or other oxygen modifying approaches (in patient tumours with low CD8+ counts) or randomised to standard-of-care alone or with an ICI (high CD8+ counts). Here, CD8A is linked to neoplasm.